HRT myths and facts: checking the claim before changing treatment

Which HRT claims should you question?

Menopause HRT is effective treatment for specific symptoms, but a reassuring headline or alarming anecdote cannot establish which product fits your health history. The useful question is usually narrower: which hormone, route, treatment purpose, population and outcome does this claim describe? Systemic estrogen, low-dose vaginal estrogen and testosterone for a defined sexual-health indication are different treatments. A claim about one does not automatically describe another. [1], [2], [10]

Two opposing messages cause avoidable confusion: “every hormone is dangerous” and “everyone needs hormones to stay healthy.” Neither reflects individualized menopause care. Symptoms, age and stage, the presence of a uterus, previous disease, contraception needs and your priorities belong in the decision. Choosing treatment, declining it, or revisiting it later can each be reasonable when the decision follows accurate information and appropriate clinical assessment. [1], [2]

This guide checks common claims against their actual boundaries. It does not turn a checklist into a prescription. If a statement concerns a medicine you already use, bring its exact name and current local product information to your clinician or pharmacist rather than changing the dose or omitting a prescribed hormone yourself.

How can you check a claim before acting on it?

Start with the treatment purpose. Relief of bothersome hot flashes is different from prevention of heart disease; vaginal dryness is different from generalized fatigue; low sexual desire causing distress needs a broader assessment than a hormone level. Ask whether the evidence studied that purpose and whether the claimed benefit is a measured clinical outcome, a laboratory result or a personal impression. [1], [2], [10]

Next identify the product and population. A trial of oral conjugated equine estrogens with medroxyprogesterone acetate in postmenopausal women does not directly measure every modern estradiol patch. Conversely, that difference does not prove that every patch or progesterone combination is risk-free. Look for the route, accompanying progestogen, uterus status, age and time since menopause, and whether participants had the relevant medical history. [2], [11], [12]

Finally ask what would change your plan. Does the claim support a clinical conversation, an actual label instruction, or an unsupported universal dosing rule? A change in symptoms deserves attention even when the cause is uncertain. Your prescriber should explain the next review, signs needing earlier contact and what to do if the treatment is ineffective or unacceptable.

Does a normal hormone test rule out menopause symptoms?

No. In otherwise healthy people aged 45 or older, NICE generally identifies perimenopause and menopause from symptoms and menstrual history without routine laboratory confirmation. Hormone concentrations can fluctuate during the transition; a single reassuring result does not erase a consistent history. It also does not prove that every new symptom is menopause-related. Thyroid disease, anemia, medication effects, sleep problems and other conditions may need assessment when the history suggests them. [1]

The age and treatment context matter. Suspected premature ovarian insufficiency, younger people with uncertain symptoms, hormonal contraception and treatment-induced ovarian changes need their own diagnostic approach. Tests ordered for another suspected illness answer that illness-related question. Testosterone testing during prescribed testosterone treatment has a separate monitoring role; it is not a diagnostic test for low desire. [1], [10]

The related claim that everyone needs a “perfect” estradiol or progesterone target is also too broad. ACOG does not recommend routine adjunct hormone testing to prescribe compounded menopausal hormones, and describes limitations of salivary testing. Selected clinical testing can have a role in particular circumstances. That does not establish a universal number to chase, justify repeated self-adjustment or replace assessment of symptoms, safety and endometrial protection. [7]

Does “bioidentical” mean safer, or mean compounded?

Bioidentical describes a molecule's relationship to hormones produced in the body. It does not describe whether a product is regulator-approved, pharmacy-compounded, suitable for your indication or adequately studied. Regulated estradiol and micronized progesterone products can be bioidentical. The word does not require a custom mixture, and “natural” does not guarantee the absence of adverse effects. [7]

ACOG recommends that compounded bioidentical menopausal hormone therapy not be prescribed routinely when FDA-approved formulations exist. The FDA explains that compounded drugs are not FDA-approved and do not undergo its premarket review for safety, effectiveness and quality. Compounding can serve a legitimate need when an approved product cannot meet an individual patient's medical needs; this is different from claiming superiority for every custom hormone prescription. These are US regulatory statements, not a substitute for another country's rules. [7], [8]

Ask which approved alternatives have been considered and what specific problem compounding would solve. If an ingredient, concentration, delivery route or batch differs, an attractive name does not establish equivalent absorption or endometrial protection. Salivary panels and testimonials do not demonstrate that a particular compounded cream or pellet is safer over years of use. [3], [7]

Were the WHI findings debunked, or do they apply identically to every HRT?

Neither description is accurate. The Women's Health Initiative tested specific regimens in two separate randomized trials. The combined trial involved oral conjugated equine estrogens plus medroxyprogesterone acetate in women with a uterus; the estrogen-alone trial involved oral conjugated equine estrogens in women with a previous hysterectomy. Their outcomes and participants cannot be merged into one generic “hormone risk.” [11], [12]

Subsequent analyses and clinical guidance added important context about age, timing, treatment purpose and absolute risk. That improves interpretation; it does not mean the original trials were retracted or that an alternative formulation has proven freedom from every outcome. Modern route choices may address particular risks, while uncertainty remains about some comparisons and long-duration use. [2]

For your own decision, ask for benefits and harms relevant to your product and baseline health. Check whether a risk is reported per year, over several years, or as a relative change. Those quantities are not interchangeable. A small relative change can have a different practical meaning in a low-risk versus high-risk population. The WHI guide separates trial findings from later interpretation rather than offering a single number for everyone.

Do recent FDA warning changes mean all risks disappeared?

No. On February 12, 2026, the FDA announced approved labeling changes for an initial six menopausal hormone products. Statements concerning cardiovascular disease, breast cancer and probable dementia were removed from those products' boxed warnings. The announcement described further submitted label proposals; it did not say every product and jurisdiction had already adopted identical information. [5]

The preceding FDA request also distinguished systemic from local treatment and retained the endometrial-cancer boxed warning for systemic estrogen-alone products. A boxed warning is a specific regulatory format, not the entire safety profile. Removing or revising one does not establish that an adverse outcome is impossible, erase remaining warnings or contraindications, or create a prevention indication. [6]

Use the current label for the exact medicine and country you are considering. If a headline appears to conflict with your leaflet, ask the pharmacist to check whether the leaflet is current and explain which change applies. US announcements do not directly amend Canadian product monographs or UK summaries of product characteristics. A clinician can discuss newer evidence while still considering the relevant approved information and your personal risks.

Are patches and vaginal treatments automatically free of systemic concerns?

Transdermal estrogen passes through the skin into the circulation. A patch or gel is systemic treatment, even though it is applied externally. Route choice can matter for some risks, but it does not remove the need to assess your medical history. If you have a uterus and use systemic estrogen, adequate endometrial protection is generally required; switching from a tablet to a patch does not cancel that requirement. [1], [3]

Low-dose vaginal estrogen primarily treats local genitourinary symptoms and has much lower systemic exposure. It can be used alone or, when needed, alongside systemic HRT. Additional progestogen is generally not recommended solely for low-dose vaginal estrogen, but this is not a rule for every vaginally administered estrogen. Some vaginal products deliver systemic treatment. Identify the actual product rather than deciding from the word “vaginal” or the shape of an applicator. [1], [2]

After breast cancer, local treatment needs a separate discussion: nonhormonal options, persistent symptoms, current cancer treatment and the uncertainty about recurrence all matter. NICE calls for specialist involvement in relevant circumstances, including aromatase-inhibitor use. Low exposure is not zero exposure and does not justify changing cancer therapy yourself. The vaginal-estrogen guide explains these distinctions. [1]

Is HRT contraception, or something you must postpone until periods stop?

HRT is not contraception. Irregular or absent periods do not always establish that pregnancy is impossible, particularly during perimenopause or while using medicines that affect bleeding. The contraceptive method, age, menstrual history and treatment context determine what protection is needed and when it can stop. Ask for a plan rather than applying someone else's final-period date. [9]

Treatment of menopause-associated symptoms does not always have to wait until periods cease. A clinician can discuss appropriate treatment during perimenopause, while choosing the hormonal schedule and contraception together. Sequential versus continuous combined treatment is a clinical decision; a friend's calendar is not a prescription for your stage. [1], [3], [9]

Also distinguish contraceptive effectiveness from protection of the uterine lining during estrogen treatment. Not every progestogen-containing contraceptive has an established role for both purposes. The particular intrauterine device, its insertion date and its approved or guideline-supported duration matter. Bring the device record or contraceptive pack, and ask the prescriber to write down which role each component serves. [3], [9]

Does everyone need HRT to prevent heart disease, dementia or weight gain?

No. NICE advises against offering HRT for primary or secondary prevention of cardiovascular disease or for prevention of dementia. These recommendations do not mean that a person with symptoms should ignore treatment; they separate the treatment indication from unsupported prevention promises. Blood pressure, lipids, smoking, diabetes, physical activity and other prevention decisions still require their own care. [1]

Hormone therapy can prevent bone loss and reduce fractures, but whether it is the right bone-related option depends on age, symptoms, fracture risk, contraindications and alternatives. NAMS describes a generally favorable benefit-risk balance for bothersome vasomotor symptoms and bone-loss prevention in women younger than 60 or within 10 years of menopause, without contraindications. That is a conditional statement, not a rule that everyone should start, nor reassurance for every person outside or inside that range. [2]

Weight, muscle function and fatigue should not be turned into universal hormone-dose targets. NAMS describes only a small effect on menopause-associated abdominal adipose accumulation and weight gain. Symptom improvement can make everyday activity easier without establishing HRT as a weight-loss treatment. The heart and bone guide and weight guide explain these separate questions. [2]

Must everyone wait out bleeding, or stop treatment at a fixed birthday?

Neither rule is safe. Some unscheduled bleeding can occur after starting or changing systemic HRT, but timing is only part of assessment. NICE describes bleeding in the first 6 months after starting or within 3 months of a change, with prompt medical help for bleeding beyond these periods. The BMS pathway also considers heavy or prolonged bleeding and risk factors that can require earlier investigation. Do not use the calendar as permission to ignore significant symptoms. [1], [4]

Ordinary review is generally at 3 months and annually thereafter, with earlier review for concerns. If a treatment is ineffective, poorly tolerated or difficult to use, ask for reassessment instead of silently stopping the protective component or adding extra estrogen. New illness, bleeding, treatment preferences and changing risks can all alter the plan. [1], [3]

NAMS states that there is no general rule requiring systemic HRT to stop at age 65. It also emphasizes limited safety evidence in older low-risk women and the need for counseling, regular risk-benefit assessment and shared decisions. Continuing an established treatment and starting it for the first time later in life are different clinical questions. A birthday alone is not enough to answer either one. [2]

Is testosterone for women always unlicensed in the UK?

That blanket claim is outdated. The MHRA-authorized AndroFeme summary of product characteristics identifies an indication for hypoactive sexual desire disorder in postmenopausal women on optimized HRT, after other causes have been considered. Its specific product instructions, monitoring and safety limitations matter. This does not mean every testosterone preparation, every low-desire complaint or every jurisdiction has the same authorization. [10]

NICE's testosterone recommendation includes a note referring to the licensing position in November 2015. Treat a dated note as dated context, not proof of the current status of all products. Testosterone is not a universal treatment for energy, muscle gain, cognition or relationship difficulties. Low desire causing distress deserves discussion of pain, medicines, mood, relationships and other contributors before a hormone is assumed to be the answer. [1], [10]

What do public accounts add, and what can they mislead us about?

Selected public accounts show that people can receive confusing calendars, notice only partial benefit, or feel uncertain when bloating or mood changes follow treatment. Other accounts express strong confidence that everyone should use HRT. Those experiences help explain why an explicit purpose, safety plan and follow-up are useful; they do not establish prevalence or predict your response. [13], [14]

The directly accessible Reddit discussion and the indexed Mumsnet opening and available replies were read for these themes. Unsupported biochemical explanations, universal hormone advice, user-supplied schedules and personal histories were not adopted as clinical recommendations. People who post online are a selected group, and an improvement occurring after treatment does not establish the cause of every change.

What should you record before revisiting a claim?

Record the claim and the practical question it creates. Add the exact product, route, prescribed schedule, contraceptive method and date of any change. Choose a small number of symptoms or daily effects that matter to you, such as disrupted sleep or discomfort during activity. Note bleeding and missed treatment separately, including when you sought advice. This is preparation for discussion, not a hormone calculation.

Bring the relevant leaflet, device information and your medication list. Ask which finding would change treatment, which concern needs earlier contact and whether the source actually describes your situation. A tracking app can help organize the chosen schedule and notes; it cannot verify a social-media claim, diagnose another illness or determine whether your dose is safe. Keep the clinical decision with the appropriate care team.

Common questions about HRT myths

Does everyone need a blood test before starting HRT?

No. For otherwise healthy people aged 45 or older, NICE generally uses symptoms and menstrual history rather than routine hormone confirmation. Tests can still be useful for another suspected condition or a different diagnostic context, including younger age or suspected premature ovarian insufficiency. Ask what question a proposed test answers and how the result would change care. The testing section separates diagnosis from selected treatment monitoring; a normal result is not a reason to dismiss symptoms. [1], [7]

Is a compounded product automatically more personal or safer?

No. A custom formulation does not by itself demonstrate superior effectiveness, consistent absorption or long-term safety. ACOG recommends regulated alternatives when available, while the FDA recognizes compounding for individual medical needs that approved products cannot meet. Ask what specific problem is being solved and which alternatives have been considered. The bioidentical section distinguishes molecular terminology from approval status; the words “natural” and “bioidentical” cannot replace product-level evidence or adequate uterine protection. [3], [7], [8]

Did the FDA say breast cancer can no longer occur with HRT?

No. Its February 2026 announcement described removal of selected statements from the boxed warnings of an initial six products. That regulatory format is only part of the prescribing information and does not establish zero risk for every medicine or person. Check the current local label and the evidence relevant to your treatment rather than applying a headline to all hormones. The regulatory section explains the scope and the separate retained endometrial warning for systemic estrogen alone. [5], [6]

Can I omit progesterone because I use a patch?

Do not omit a prescribed protective component on that basis. A patch delivers systemic estrogen, and people with a uterus generally need adequate endometrial protection with systemic treatment. The appropriate component and schedule depend on the actual estrogen treatment and clinical context. Low-dose local vaginal estrogen is a separate situation; its usual protection approach does not transfer to a patch. The route section explains the distinction, and your prescriber should review intolerance rather than leaving protection unresolved. [1], [3]

Is it too early to ask about treatment if I still have periods?

No. Perimenopause-associated symptoms can be discussed while periods continue, but the schedule and contraception need to fit your situation. HRT does not prevent pregnancy, and a contraceptive's role is not automatically identical to endometrial protection during estrogen treatment. Bring your menstrual history and contraceptive details, especially an intrauterine device's insertion record. The contraception section describes the decisions to make together; do not copy a friend's sequential or continuous calendar as your own instructions. [1], [3], [9]

Must I stop HRT at 65?

There is no universal stopping rule at that age in NAMS guidance. Continued treatment can be considered for selected people with persistent symptoms after discussion and regular review, while evidence about long-term safety in older low-risk users remains limited. Starting treatment later and continuing an established treatment require different assessments. The duration section explains why symptoms, new illness, risks and preferences matter more than a birthday alone; it does not promise indefinite treatment is appropriate for everyone. [2]

Should I ignore bleeding until the settling-in period ends?

No. The time since starting or changing treatment helps interpret bleeding, but heavy or prolonged bleeding and risk factors can justify earlier assessment. NICE advises prompt medical help for bleeding beyond its starting or change-related windows, and BMS provides a more detailed assessment pathway. Record the bleeding pattern and contact your care team when concerned rather than using a waiting rule. The review section explains the distinction between routine follow-up and symptoms needing an earlier clinical decision. [1], [4]

Does every woman with low desire need testosterone?

No. Distressing low desire needs assessment of pain, medicines, mood, relationship factors and other causes before treatment is chosen. UK AndroFeme has a defined postmenopausal HSDD indication on optimized HRT and product-specific monitoring; that authorization does not cover every testosterone use or make a blood level diagnostic. The testosterone section explains the current licensing distinction. A useful first step is to describe the difficulty and its effect on you, then discuss suitable options with a qualified clinician. [1], [10]

Glossary

Terms used in assessment and care.

Perimenopause

The transition toward menopause, with changing ovarian hormone patterns and possible symptoms.

Menopause

Usually identified after 12 months without a period when hormonal contraception does not explain the absence.

Postmenopause

The stage after menopause; symptoms can continue.

Estrogen

A hormone class that includes estradiol.

Estradiol

An estrogen made by the body and used in certain prescribed medicines.

Progesterone

A hormone and one member of the progestogen family.

Progestogen

A family of progesterone-like medicines; some provide uterine protection with estrogen.

Endometrium

The lining inside the uterus.

HRT / MHT

Hormone replacement therapy; menopausal hormone therapy in this guide.

Systemic treatment

Treatment reaching the wider body through the circulation.

Local vaginal estrogen

A low-dose product intended mainly for genitourinary symptoms.

Vasomotor symptoms

Hot flashes and night sweats.

Genitourinary syndrome of menopause

A group of menopause-associated vaginal, sexual and urinary symptoms.

Hysterectomy

Surgical removal of the uterus; the extent of surgery matters.

Sequential combined HRT

Estrogen through the cycle with progestogen on specified days.

Continuous combined HRT

Estrogen and progestogen supplied continuously.

Contraception

A method intended to prevent pregnancy; menopausal HRT is not one.

Bioidentical

A molecular description, not proof of product approval or superior safety.

Compounded preparation

A medicine prepared for an individual medical need; approval and standards depend on jurisdiction.

Boxed warning

The most prominent US FDA warning format; not the complete prescribing information.

Indication

The defined purpose for which a product is prescribed or authorized.

Contraindication

A clinical or label circumstance in which a treatment should not be used.

Absolute risk

An event frequency over a defined period in a defined population.

Relative risk

A comparison of event risks; it does not itself give the baseline event frequency.

Randomized trial

Research assigning treatment by chance to compare outcomes.

Surrogate outcome

A measurement used as a proxy; it is not necessarily the clinical event of interest.

HSDD

Hypoactive sexual desire disorder, involving clinically relevant low desire and distress.

Shared decision

A decision combining relevant clinical information and a person’s priorities with their care team.

Endometrial protection

Adequate protection of the uterine lining during systemic estrogen treatment.

Monitoring

Follow-up appropriate to the treatment, history and concerns; not one universal test panel.

Regulatory status

The product’s authorization and labeling in a particular jurisdiction.

How was this guide researched?

Source selection and limits

Current NICE and BMS guidance, original FDA compounding and 2025/2026 labeling statements, full ACOG consensus, and the original NAMS PDF clinical statement sections were checked. The NAMS reference appendix was not exhaustively reviewed. Original WHI trial access is described individually in the bibliography; interpretation does not claim a modern-regimen trial. The UK MHRA AndroFeme SmPC was checked in full for its specific indication and monitoring boundaries. Public community access is distinguished: direct Reddit opening/comments versus indexed Mumsnet opening/available replies after a failed direct fetch. No hormone targets, copied schedules or universal prevention claims were adopted.

This is an AI-assisted Doserly editorial guide checked October 3, 2026. No independent clinician review is claimed. Doserly develops a commercial tracking app. Practical record-keeping suggestions are editorial advice, not a validated diagnostic scale or clinical-monitoring system. Material new guidance, labels or safety information trigger earlier source review.

Sources